1 |
Wolchok J.D, Saenger Y, The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation, The Oncologist 2008;13:Supplement 4-29.
DOI
|
2 |
Buchbinder E. I, Desai A, CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of their Inhibition. Am J ClinOncol 2016;39:98-106.
|
3 |
Bardhan K, Anagnostou T, Boussiotis V.A, The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol 2016;7:550:1-17.
|
4 |
Shi L, Chen S, Yang L, et al. The Role of PD-1and PD-L1 in T-cell Immune Suppression in Hematological Malignancies. J Hematol Oncol 2013;6:74-80.
|
5 |
Hodi F.S, O'Day S.J, McDermott D.F, et al. Improved Survival with Ipilimumb in Patients with Metastatic Melanoma. N Engl J Med 2010;363:711-23.
DOI
|
6 |
Graziani G, Tentori L, Navarra P, Ipilimumab: A Novel Immunostimulatory Monoclonal Antibody for the Treatment of Cancer. Pharmacol Res 2012;65:9-22.
DOI
|
7 |
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015;373:23-34.
DOI
|
8 |
Hellmann M.D, Rizvi N.A, Goldman J.W, et al. Nivolumab plus ipilimumab as First-line Treatment for Advanced Non-Small-Cell Lung Cancer(CheckMate 012):Results of an Open-Label, Phase 1, Multicohort Study. Lancet Oncol 2017;18: 31-41.
|
9 |
Robert C, Long G.V, Brady B, et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med 2015;372:320-30.
DOI
|
10 |
Ribas A, Puzanov I, Dummer R, et al. Pemtrolizumab versus Investigator-Choice Chemotherapy for Ipilimumab-Refractory Melanoma (KEYNOTE-002): a randomized, controlled, phase 2 trial. Available from www.thelancet.com/oncology. 2015;16:908-18.
DOI
|
11 |
Topalian S.L, Hodi S. Brahmer J.R, et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med 2012; 366:2443-54.
DOI
|
12 |
Rosenberg J.E, Hoffman-Censits J, Powles T, et al. Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma who have Progressed Following Treatment with Platinum-Based Chemotherapy: A Single Arm, phase 2 trial. Lancet 2016;387:1909-20.
|
13 |
Kaufman H, Russell J, Hamid O, et al. Avelumab in Patients with Chemotherapy-Refractory Metastatic Merkel Cell Carcinoma: A Multicenter, Single-Group, Open-Label, Phase 2 Trial. Lancet Oncol 2016; 17:1374-85.
|
14 |
Massard C, Gordon M. S, Sharma S, et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer. J ClinOncol 2016;34:3119-26.
DOI
|
15 |
Bellmunt J, Powles T, Vogelzang N.J, A Review on the Evolution of PD-1/PD-L1 immunotherapy for Bladder Cancer: The Future is Now. Cancer Treat Rev 2017;54:58-67.
DOI
|
16 |
Topalian S.L, Taube J.M, Anders R.A., et al. Mechanism-Driven Biomarkers to Guide Immune Checkpoint Blockade in Cancer Therapy. Nat Rev Cancer 2016;16:275-87.
DOI
|
17 |
Teixido C, Gonzalez-Cao M, Karachaliou N, et al. Predictive Factors for Immunotherapy in Melanoma. Ann Transl Med 2015;3:208.
|
18 |
Taube J.M, Klein A, Brahmer J. R, et al. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy. Clin Cancer Res 2014; 20: 5064-74.
DOI
|
19 |
Robert C, Schachter J, Long G.V, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015;372:2521-32.
|
20 |
Messina J, Fenstermacher D.A, Eschrich S, et al. 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy. Sci Rep 2012;2:765-71.
DOI
|
21 |
Zaretsky J.M, Diaz A.G, Shin D.S, et al. Mutations Associated with Acquired Resistance to PD-1 Blocked in Melanoma. N Engl J Med 2016;375:819-29.
DOI
|
22 |
Pennock G.K, Chow L. Q.M, The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. The Oncologist 2015;20:812-22.
DOI
|
23 |
Snyder A, Makarov V, Merghoub T, et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. N Engl J Med 2014;371:2189-99.
|
24 |
Heppt M.V, Dietrich C, Graf S.A, Ruzicka T, Tietze J.K, Berking C, The Systemic Management of Advanced Melanoma in 2016. Oncol Res Treat 2016;39:635-42.
|
25 |
Gibney G.T, Weiner L.M, Atkins M.B, Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy. Lancet Oncol 2016;16: e542-51.
|
26 |
Ansell S.M, Lesokhin A.M, Borrello I, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. N Engl J Med 2015;372:311-9.
DOI
|
27 |
Weber J.S, D'Angelo S.P, Minor D, et al. Nivolumab Versus Chemotherapy in Patients with Advanced Melanoma who Progressed after Anti-CTLA-4 Treatment (CheckMate 037): A Randomized, Controlled, Open-Label, Phase 3 Trial. Lancet Oncol 2015;16:375-84.
DOI
|
28 |
Sadraei N. H, Sikora A. G, Brizel D. M, Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer. asco.org/edbook 2016;e277-81.
|
29 |
Rozali E.N, Hato S.V, Robinson B.W, Lake R.A, Lesterhuis W.J, Programmed Death Ligand 2 in Cancer-Induced Immune Suppression, Clinical and Developmental Immunology. 2012; Article ID 656340:1-8.
|
30 |
Rizvi N.A, Mazieres J, Planchard D, et al. Activity and Safety of Nivolumab, an Anti-PD-1 Immune Checkpoint inhibitor, for Patients with Advanced, Refractory Squamous Non-Small-Cell Lung Cancer (CheckMate 063): A Phase 2, Single-Arm Ttrial. Lancet Oncol 2015; 16:257-65.
|
31 |
Apolo A.B, Infante J.R, Balmanoukian A, et al. Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. J Clin Oncol 2016;35:2117-26.
|
32 |
LiY, Li F, Jiang F, et al. A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway &Translational Blockade of Immune Checkpoints. Int J Mol Sci 2016;17:1151-73.
DOI
|
33 |
Yu H, Boyle T. A, Zhou C, Rimm D. L, Zhou C, Hirsh F.R, PD-L1 Expression in Lung Cancer. J Thorac Oncol 2016;11:964-75.
|
34 |
Garon E.B, Rizvi N. A, Hui, et al. Pembrolizumab for the Treatmentof Non-Small-Cell Lung Cancer. N Engl J Med. 2015;372:2018-28.
DOI
|
35 |
Nghiem P.T, Bhatia S, Lipson E.J, et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med 2016;374:2542-52.
DOI
|
36 |
Mozzillo N., Ascierto P.A., Melanoma: the Role of Surgery in the Era of New Therapies. J Transl Med 2014;12:195.
DOI
|
37 |
Patel M.R, Ellerton J, Agrawal M, et al. Avelumab (MSB0010718C; Anti-PD-L1) in Patients with Metastatic Urothelial Carcinoma Progressed after Platinum-Based Therapy or Platinum Ineligible. Ann Oncol 2016;27:Supplement 6: vi266-vi295.
|